1) 厚生労働省:令和2年度版 厚生労働省白書 平均寿命の推移.
2) 厚生労働省:令和元年(2019)人口動態統計月報年計(概数)の概況.
3) 厚生労働省:令和元年簡易生命表の概況.
4) Sturgeon KM, Deng L, Bluethmann SM, et al:A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 40:3889-3897, 2019
5) Armenian SH, Xu L, Ky B, et al:Cardiovascular Disease Among Survivors of Adult-Onset Cancer:A Community-Based Retrospective Cohort Study. J Clin Oncol 34:1122-1130, 2016
6) Cardinale D:[A new frontier:cardio-oncology]. Cardiologia 41:887-891, 1996
7) Felker GM, Thompson RE, Hare JM, et al:Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 342:1077-1084, 2000
8) Perez IE, Taveras Alam S, Hernandez GA, et al:Cancer Therapy-Related Cardiac Dysfunction:An Overview for the Clinician. Clin Med Insights Cardiol 13:1179546819866445
9) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al:2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology(ESC). Eur Heart J 37:2768-2801, 2016
10) Armenian SH, Lacchetti C, Barac A, et al:Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers:American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 35:893-911, 2017
11) Curigliano G, Lenihan D, Fradley M, et al. ESMO Guidelines Committee. Electronic address:clinicalguidelines@esmo.org:Management of cardiac disease in cancer patients throughout oncological treatment:ESMO consensus recommendations. Ann Oncol 31:171-190, 2020